Table 2. The prognostic significance of SERPINB5 mRNA in non-small lung cancer by Kaplan–Meier plotter.

Clinicopathological features	OS		PFS
	HR	P	HR	P
Sex
Male	1.69 (1.41–2.03)	9.40E-09	1.59 (1.21–2.09)	8.20E-04
Female	1.55 (1.23–1.96)	1.90E-04	1.32 (0.94–1.87)	1.10E-01
Smoking
Yes	1.7 (1.38–2.09)	3.90E-07	1.49 (1.12–1.97)	5.60E-03
No	2.23 (1.27–3.89)	3.90E-03	1.83 (1.13–2.96)	1.30E-02
Histology
Adenocarcinoma	1.88 (1.49–2.38)	7.10E-08	1.96 (1.44–2.68)	1.60E-05
Squamous	0.79 (0.617–1.03)	8.10E-02	1.68 (0.97–2.9)	6.10E-02
T
1	1.71 (1.28–2.3)	2.80E-04	1.49 (0.81–2.75)	2.00E-01
2	1.53 (1.17–1.99)	1.70E-03	0.82 (0.6–1.11)	1.90E-01
3	0.66 (0.37–1.19)	1.67E-01	0.62 (0.22–1.76)	3.60E-01
4	0.64 (0.34–1.23)	1.80E-01
N
0	1.53 (1.24–1.89)	7.50E-05	1.31 (0.91–1.87)	1.40E-01
1	1.37 (1–1.87)	5.00E-02	0.74 (0.47–1.17)	1.90E-01
2	1.48 (0.91–2.41)	1.10E-01	2.73 (1.22–6.09)	1.10E-02
TNM stage
I	2.08 (1.59–2.72)	4.80E-08	2.05 (1.31–3.2)	1.30E-03
II	1.23 (0.86–1.78)	2.60E-01	0.4 (0.22–0.73)	1.70E-03
III	0.76 (0.43–1.34)	3.40E-01
Chemotherapy
Yes	2.41 (1.58–3.68)	2.60E-05	1.66 (1.08–2.57)	2.00E-02
No	2.26 (1.62–3.17)	1.00E-06	1.57 (1.03–2.37)	3.30E-02
Radiotherapy
Yes	3.94 (2.2–7.05)	9.30E-07	2.16 (1.24–3.78)	5.70E-03
No	1.76 (1.22–2.53)	2.00E-03	1.37 (0.89–2.12)	1.50E-01
Surgery success
Surgical margins negative	2.25 (1.79–2.84)	1.40E-12	1.85 (1.39–2.46)	2.20E-05